摘要
目的从环磷酸腺苷(c AMP)信号通路角度探讨复方柴归方超临界CO2提取物的抗抑郁作用机制。方法采用慢性温和不可预知应激(CUMS)程序对大鼠进行造模,以高、中、低剂量复方柴归方超临界CO2提取物及文拉法辛为干预药物,检测各组大鼠海马组织中c AMP、蛋白激酶A(PKA)、环磷酸腺苷反应原件结合蛋白(CREB)、脑源性神经生长因子(BDNF)水平及其相应m RNA水平。结果与对照组比较,模型组大鼠海马组织中c AMP、PKA、p-CREB、BDNF水平显著下降(P<0.05、0.01),复方柴归方干预后,与模型组比较,各剂量组c AMP、PKA、p-CREB、BDNF水平均出现回调(P<0.05、0.01);同时,模型组大鼠海马组织中酪氨酸激酶B(TrkB)、PKA、p-CREB、BDNF的m RNA水平显著下降(P<0.05、0.01),复方柴归方干预后,与模型组相比,各剂量组Trk B、PKA、p-CREB、BDNF的m RNA水平均出现回调(P<0.05、0.01)。结论复方柴归方超临界CO2提取物可通过调控c AMP-PKA-CREB-BDNF信号通路发挥抗抑郁作用。
Objective To investigate the antidepressant mechanism of supercritical CO2 extract from Compound Chaigui Precription from the perspective of cAMP signaling pathway. Methods The rats model were established by chronic unpredictable mild stress (CUMS). The rats were administrated with high, medium and low doses of supercritical CO2 extract from Compound Chaigui Precription and venlafaxine as intervention drugs. The protein expression levels of cAMP, PKA, p-CREB and BDNF in tissues and their corresponding mRNA levels were explored for their antidepressant mechanism. Results Compared with the blank group, the expression levels of cAMP, PKA, p-CREB and BDNF in the hippocampus of the model group were significantly decreased (P < 0.05, P < 0.01). After the intervention of the Compound Chaigui Precription, compared with the model group, there was a significant difference in the callus of each dose group. At the same time, the mRNA levels of TrkB, PKA, p-CREB and BDNF in the hippocampus of the model group were significantly decreased (P < 0.05, P < 0.01). After the intervention, there was a callback in each dose group compared with the model group, with significant differences. Conclusion Supercritical CO2 extract from Compound Chaigui Precription can exert antidepressant effect by regulating cAMP-PKA-CREB-BDNF signaling pathway.
作者
向欢
高耀
刘少博
韩雨梅
秦雪梅
田俊生
XIANG Huan;GAO Yao;LIU Shao-bo;HAN Yu-mei;QIN Xue-mei;TIAN Jun-sheng(School of Physical Education, Shanxi University, Taiyuan 030006, China;Modern Research Center of Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China)
出处
《中草药》
CAS
CSCD
北大核心
2019年第14期3368-3373,共6页
Chinese Traditional and Herbal Drugs
基金
国家科技重大专项课题(2017ZX09301047)
山西省科技重点研发计划(201603D3113013)
山西省科技重点研发计划(201603D321077)
山西省重点实验室项目(201605D111004)
山西省科技创新重点团队项目(201605D131045-18)